On September 27th, Sanofi announced that Dapitumab Injection has been approved by the China National Medical Products Administration for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. This approval is based on the results of two milestone Phase III clinical trials, which showed that dabigatur (once every two weeks) significantly reduced acute exacerbations and improved lung function.